-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Zhitong Finance App News, Peger Biopharmaceutical-B (02565.HK) announced that the core innovative drug product Vipenatide injection (trade name: Pidacan®, hereinafter referred to as “Pidacan®”) was successfully included in the “2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” recently announced by the National Health Security Administration.
Share
Listen to the news
According to Zhitong Finance App News, Peger Biopharmaceutical-B (02565.HK) announced that the core innovative drug product Vipenatide injection (trade name: Pidacan®, hereinafter referred to as “Pidacan®”) was successfully included in the “2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” recently announced by the National Health Security Administration.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending